All In Biotech

Drug Trial Radar · NCT01903252

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/Day for the Treatment of Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Aug 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 817 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

817

Actual

Start

Jul 2013

Primary completion

May 2016

Study completion Nov 2016

Sponsor

Lead sponsor
Tillotts Pharma AGIndustry
Sponsor type
Industry
First posted
Jul 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05. This study investigated whether TP05 is as good as (non-inferior to) Asacol™(1). (1)The trademark Asacol™ is registered in over 55 countries as Asacol™ and as Octasa™, Fivasa™, Lixacol™, Asacolon™ in the United Kingdom, France, Spain and Ireland, respectively. The rights to Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg.

Conditions

  • Acute Ulcerative Colitis

Interventions

  • TP05Drug

    3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)

  • Asacol 400 mgDrug

    3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Period 1: Clinical and Endoscopic RemissionTime frame: Week 8
  2. Period 2: Clinical Response, Open-Label Extended InductionTime frame: Week 16
  3. Period 3: Clinical RemissionTime frame: Week 38

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tillotts Pharma AG

    Rheinfelden, Baslerstrasse 15, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.